Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Remember:

The Company will receive from Alfasigma an initial payment, plus be eligible for additional payments based on certain milestones, totaling over $24 million, and receive a 6 percent royalty (net sales) based on the successful marketing of Brilacidin for UP/UPS. The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.


We wait with ~ 4 million in cash on hand w very little overhead


We now also wait on our 4 million investment in ……

As we wait we also field interest in B for viruses and BOM